CRYO CHECK FACTOR V DEFICIENT PLASMA

K971223 · Precision Biologicals, Inc. · GJT · Jul 22, 1997 · Hematology

Device Facts

• Record ID: K971223
• Device Name: CRYO CHECK FACTOR V DEFICIENT PLASMA
• Applicant: Precision Biologicals, Inc.
• Product Code: GJT · Hematology
• Decision Date: Jul 22, 1997
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 864.7290
• Device Class: Class 2

Intended Use

CryoCheck Factor V Deficient Plasma is human plasma deficient in the factor V coagulation protein while having all other coagulation factors within normal limits. It is indicated for use to assess factor V deficiencies in in vitro clot-based factor V assays using the one stage prothrombin time.

Device Story

CryoCheck Factor V Deficient Plasma is human plasma depleted of coagulation factor V while maintaining normal levels of other coagulation factors. Used in clinical laboratories by technicians to perform in vitro clot-based factor V assays via one-stage prothrombin time (PT). Patient plasma sample is mixed with the deficient plasma; degree of PT correction is proportional to the patient's factor V level. Assists clinicians in diagnosing factor V deficiency, which can compromise in vivo hemostasis.

Clinical Evidence

No clinical data provided; bench testing only.

Technological Characteristics

Human plasma depleted of factor V; other coagulation factors within normal limits. Reagent for in vitro diagnostic use in clot-based assays.

Indications for Use

Indicated for use in in vitro clot-based factor V assays using the one stage prothrombin time to assess factor V deficiencies in patients with suspected congenital or acquired coagulation factor deficiencies.

Submission Summary (Full Text)

{0}

DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Sandy Morrison
Precision Biologicals
900 Windmill Road, #100
Dartmouth, Nova Scotia
Canada B3B 1P7

Re: K971223
CryoCheck Factor V Deficient Plasma
Regulatory Class: II
Product Code: GJT
Dated: May 29, 1997
Received: June 2, 1997

Dear Ms. Morrison:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations.

JUL 22 1997

{1}

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at [phone].

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone] or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical Laboratory Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

{2}

DPB

Page 1 of 1

510(k) Number (if known): not yet issued

Device Name: CryoCheck Factor V Deficient Plasma

Indications For Use: Deficiencies in coagulation factors may have congenital or acquired etiologies and can compromise in vivo hemostasis. Factor V is a single chain glycoprotein with a molecular weight of 330,000 and is important for both intrinsic and extrinsic coagulation. Factor V deficiency is commonly diagnosed in vitro through the use of a modified prothrombin time (PT) assay. When a patient sample is mixed with factor V deficient plasma, the degree of correction of the PT is proportional to the level of Factor V in the patient plasma.

CryoCheck Factor V Deficient Plasma is human plasma deficient in the factor V coagulation protein while having all other coagulation factors within normal limits. It is indicated for use to assess factor V deficiencies in in vitro clot-based factor V assays using the one stage prothrombin time.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☑ OR
(Per 21 CFR 801.109)

Over-The-Counter Use
(Optional Format 1-2-96)
(Division of Clin. 1-2-96)
510(k) Number 97/223